Immunonkologische Therapieoptionen des nicht-muskelinvasiven Urothelkarzinoms
Author:
Publisher
Springer Science and Business Media LLC
Subject
Urology
Link
https://link.springer.com/content/pdf/10.1007/s00120-020-01233-6.pdf
Reference14 articles.
1. Babjuk M, Burger M, Comperat EM et al (2019) European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) – 2019 update. Eur Urol 76:639–657
2. Mannas MP, Lee T, Nykopp TK et al (2018) A risk-stratified approach to the management of high-grade T1 bladder cancer. Curr Opin Urol 28:563–569
3. Gakis G, Todenhofer T, Braun M et al (2015) Immunohistochemical assessment of lymphatic and blood vessel invasion in T1 urothelial carcinoma of the bladder. Scand J Urol 49:382–387
4. Sylvester RJ, van der Meijden AP, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964–1970
5. Packiam VT, Lamm DL, Barocas DA et al (2018) An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. Urol Oncol 36:440–447
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Nicht muskelinvasives Urothelkarzinom der Harnblase;Im Fokus Onkologie;2022-10
2. Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review;Urologic Oncology: Seminars and Original Investigations;2022-09
3. Adjuvante Instillationstherapie des nicht muskelinvasiven Harnblasenkarzinoms – neue Optionen abseits von BCG und Mitomycin;TumorDiagnostik & Therapie;2022-06-28
4. Adjuvante Instillationstherapie des nicht muskelinvasiven Harnblasenkarzinoms – neue Optionen abseits von BCG und Mitomycin;Aktuelle Urologie;2022-02-16
5. Nicht muskelinvasives Urothelkarzinom der Harnblase;Uro-News;2022-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3